PD-1 × VEGF bispecifics after ivonescimab
That MK-2010’s data are entirely from China is itself an industry signal: Merck is willing to refill post-PD-1 through this path.
#AACR26
@AACR
· PD-1×VEGF bispecifics
@chuminhua432
's three #AACR26 posts on PD-1×VEGF bispecifics together — JS207 in HCC (CT159), JS207 in MSS CRC (CT152), and MK-2010 first-in-human (CT057, oral April 20):
1/ Class context
PD-1 × VEGF bispecifics are an emerging I/O modality
Heat 2 · 2 likes · 0 replies · 0 reposts
Jian Zhou, Guoming Shi, Yongsheng Ge, Shuijun Zhang, Xiwen Huang, Shunda Du, Yong Gao, Guohong Han, Xiaoyong Huang, Zhenda Wang, Junliang Li, Jing Xu, Jiazheng Yan, Jianjun Zou, Jia Fan
Read the abstract →Yong Gao, Zhiwei Li, Jianwei Yang, Shuqing Jin, Yiyi Yu, Chang Wang, Xiwen Huang, Jingdong Zhang, Yanhong Gu, Shuqin Ni, Yanlai Sun, Shirong Cai, Liang Han, Xinjun Liang, Haichuan Su, Chenxi Wang, Zhenyu Xu, Jing Xu, Chengbo Jia, Jianjun Zou, Lin Shen
Read the abstract →Source: The Innovation | Medicine · x.com